Pharnext S.A.

Pharnext appoints Amit Kohli as Chief Operating Officer

Pharnext to Showcase PLEOTHERAPYTM R&D Platform at the 8th Annual Global Orphan Drug Conference

Pharnext Reports Financial Results for Year-End 2017

Pharnext to Present at the H.C. Wainwright Annual Global Life Sciences Conference

Pharnext S.A.: Successful Intermediate Analysis for PLEO-CMT Phase III Clinical Trial in Charcot-Marie-Tooth Disease Type 1A

Pharnext To Attend November Investors Conferences

Pharnext announces acceptance of late breaking abstract at the 10th Clinical Trials on Alzheimer’s Disease (CTAD) Conference

Pharnext’s PLEODRUG(TM) PXT3003 to be Featured at the Upcoming Hereditary Neuropathy Foundation (HNF) Annual Patient-Centered Summit

First-Half 2017

Pharnext to Present at 4th International Neurotech Investing and Partnering Conference

Pharnext Amends the Protocol of the International Pivotal Phase 3 Trials of PXT3003 for Charcot-Marie-Tooth Disease Type 1A

Pharnext to Present at 7th Annual CEC Capital Summit

Pharnext’s PXT3003 Featured at the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) 2017 Annual Meeting

Pharnext Announces that the DSMB Recommends Continuing the Ongoing Phase 3 Trial of PXT3003 for Charcot-Marie-Tooth Disease Type 1A

Pharnext to Present at Rodman & Renshaw 19th Annual Global Investment Conference

Pharnext to Present PXT864 Data at the Alzheimer’s Association International Conference 2017

Pharnext’s PLEODRUG(TM), PXT3003, to be Featured in Multiple Presentations at the 2017 Peripheral Nerve Society Meeting

Pharnext to Showcase Pioneering PLEOTHERAPY(TM) R&D Platform at 6th Annual Drug Repositioning, Repurposing and Rescue Conference

Pharnext Announces Strategic Partnership with Tasly, a Leading Chinese Pharmaceutical Group

Pharnext Reports Year End 2016 Financial Results

Pharnext gibt Umplatzierung von Aktien ihres Altaktionärs bekannt und stärkt damit die Position von Kernaktionären

Pharnext to Present New PXT864 Synergy Data at AD/PDTM 2017, the 13th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders

Pharnext Announces Initiation of Phase 3 Extension Study PLEO-CMT-FU of PXT3003 for Treatment of Charcot-Marie-Tooth Disease Type 1A

Pharnext gibt Forschungs- und Entwicklungsvereinbarung mit Galapagos zum Aufbau einer neuen Pipeline synergistischer Wirkstoffkombinationen bekannt